Furthermore, mutation of CSNK1A1 is most commonly associated with myelodysplastic syndromes (5q deletion syndrome) and therefore CK1α has been identified as a promising therapeutic target for these patients [37,38]. This evidence concerns the gene CSNK1A1 and myelodysplastic syndrome associated with isolated del(5q).